within Pharmacolibrary.Drugs.ATC.C;

model C09DX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.025,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Fixed combination tablet of irbesartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and hydrochlorothiazide (a thiazide diuretic) used for the treatment of essential hypertension in adults; currently approved and used in clinical practice when multi-drug therapy is indicated.</p><h4>Pharmacokinetics</h4><p>Estimated composite pharmacokinetic parameters for healthy adult subjects, based on published data of individual components. No direct study of triple-combination PK model found.</p><h4>References</h4><ol><li>Giuseppe Derosa, Ilaria Ferrari, Arrigo F G Cicero,Irbesartan and hydrochlorothiazide association in the treatment of hypertension.,Current vascular pharmacology,2009<a href='https://pubmed.ncbi.nlm.nih.gov/19355995/'>https://pubmed.ncbi.nlm.nih.gov/19355995/</a></li><li>Katherine F Croom, Monique P Curran, Karen L Goa, Caroline M Perry,Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.,Drugs,2004<a href='https://pubmed.ncbi.nlm.nih.gov/15101793/'>https://pubmed.ncbi.nlm.nih.gov/15101793/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09DX07;
